HP
SUPN icon

Harbourvest Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Harbourvest Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-103,192
Closed -$1.57M – 24
2016
Q1 		$1.57M Sell
103,192
-172,561
-63% -$2.25M 0.67% 8
2015
Q4 		$3.71M Buy
+275,753
New +$4.27M 1.35% 7

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbourvest Partners's SUPN Position: Q2 2016 in Review

Harbourvest Partners sold out of Supernus Pharmaceuticals (SUPN) in Q2 2016, closing a stake of 103,192 shares — an estimated $1.57M sold.

Harbourvest Partners first reported a position in SUPN in Q4 2015 and held it in 2 quarters. The position peaked at $3.71M in Q4 2015. 215 funds tracked by Wall St. Rank hold SUPN as of Q2 2016.

  • Harbourvest Partners reported no remaining Supernus Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Harbourvest Partners sold 103,192 Supernus Pharmaceuticals shares in Q2 2016, an estimated $1.57M.
  • Harbourvest Partners first reported a position in Supernus Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Harbourvest Partners's Supernus Pharmaceuticals position peaked at $3.71M in Q4 2015.
  • 215 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2016.

Based on Harbourvest Partners's 13F filing for Q2 2016, filed 15 Aug 2016.